APPLAUSE - Study of efficacy and safety of LNP023 in primary IgA nephropathy patients
Projektleiter:
Projektbearbeiter:
Claudia Piehler,
Dr. med. Jan Schiefer,
Dr. med. Ben Hammoud
Finanzierung:
Industrie;
Novartis Phase III Clinical Study
A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in IgA nephropathy patients.
A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in IgA nephropathy patients.
Kontakt

Prof. Dr. Peter R. Mertens
Otto-von-Guericke-Universität Magdeburg
Universitätsklinik für Nieren- und Hochdruckkrankheiten, Diabetologie und Endokrinologie
Leipziger Str. 44
39120
Magdeburg
Tel.:+49 391 6713236
weitere Projekte
Die Daten werden geladen ...